ALTA 2618
Alternative Names: ALTA-2618Latest Information Update: 06 Feb 2026
At a glance
- Originator Alterome Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Breast cancer; Endometrial cancer
Most Recent Events
- 02 Feb 2026 Alterome Therapeutics plans a registrational trial for Solid tumour
- 22 Aug 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, Spain, South Korea, Japan, Australia (PO)
- 22 Aug 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO)